Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Paolillo, Emily W., Wise, Amy, Kaye, Jeffrey A., Beattie, Zachary , Dhanam, Sreya, Casaletto, Kaitlin B. , Saloner, Rowan, Mendez, Mario F., Vandevrede, Lawren, Ljubenkov, Peter A. , Seeley, William W., Gorno-Tempini, Maria Luisa, Miller, Bruce L., Heuer, Hilary W. , Forsberg, Leah K., Kornak, John , Boeve, Bradley F., Boxer, Adam L., Rosen, Howard J., Walsh, Christine M., Staffaroni, Adam M., Abdullah, Muhammad, Apostolova, Liana , Ece, Bayram, Botha, Hugo, Brushaber, Danielle , Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S., Dickerson, Bradford, Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily , Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana M., Galasko, Douglas R., Gavrilova, Ralitza, Gendron, Tania, Geschwind, Daniel, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Grossman, Murray, Hales, Chadwick M., Hall, Matthew, Honig, Lawrence S., Hsiung, Ging-Yuek (Robin), Huang, Eric S., Huey, Edward D, Irwin, David, Johnson, Noah, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler, Kwan, Justin Y., Lago, Argentina Lario , Lapid, Maria, Lavigne, Shannon B., Lee, Suzee, Litvan, Irene, Lucente, Diane , Mackenzie, Ian R., Masdeu, Joseph C. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pascual, Belen, Paulson, Henry, Petrucelli, Leonard, Pressman, Peter, Rademakers, Rosa, Ramanan, Vijay, Ramos, Eliana Marisa , Rankin, Katherine P., Rao, Meghana, Rascovsky, Katya, Rhoads, Kristoffer , Ritter, Aaron, Rogalski, Emily, Rojas, Julio C., Savica, Rodolfo, Snyder, Allison, Sullivan, Anna Campbell, Syrjanen, Jeremy, Tartaglia, M. Carmela, Taylor, Jack, Weintraub, Sandra, Wint, Dylan , Wong, Bonnie, Yokoyama, Jennifer, Mendez, Mario F. , VandeVrede, Lawren , Paolillo, Emily W. , Wise, Amy B. , Saloner, Rowan , Forsberg, Leah Kathleen, VandeVrede, Lawren , Mendez, Mario , Paolillo, Emily W , Kaye, Jeffrey , Au-Yeung, Wan-Tai Michael , Dhanam, Sreya , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Forsberg, Leah K. , Kremers, Walter K. , Boeve, Bradley F. , Boxer, Adam L. , Rosen, Howard J. , Walsh, Christine M. , Staffaroni, Adam M. , Appleby, Brian S. , Barmada, Sami , Bozoki, Andrea C , Domoto‐Reilly, Kimiko , Galasko, Douglas , Gavrilova, Ralitza H. , Gendron, Tania F. , Geschwind, Daniel H., Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grossman, Murray, Hales, Chadwick M. , Hall, Matthew , Honig, Lawrence, Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Knopman, David, Kwan, Justin , Lavigne, Shannon B., Léger, Gabriel C. , Litvan, Irene , Mackenzie, Ian R. , Masdeu, Joseph C , McMillan, Corey T. , Mester, Carly , Molden, Joie, Pantelyat, Alexander , Pascual, Belén , Petrucelli, Leonard , Pressman, Peter , Rademakers, Rosa, Rankin, Katherine P. , Rao, Meghana , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Rojas, Julio C. , Savica, Rodolfo , Snyder, Allison , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Taylor, Jack C. , Tipton, Philip W. , Vandebergh, Marijne , Weıntraub, Sandra , Wong, Bonnie

Mayo Clinic

Neurology Open Access | February 18, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1212/wn9.0000000000000068 | PMID 41987885 Get It

A Pilot Validation Study of Plant‐Based and Allergy‐Friendly Alternative for Testing Gastric Emptying: A Randomized Trial in Healthy Participants
Abdelnaem, Nada, Carlson, Paula, Busciglio, Irene, Burton, Duane, Ryks, Michael, Johnson, Derek R., Navin, Patrick J. , Bach, Corrie R. , Paulsen, Andrew, Bartlett, David J. , Camilleri, M., Jencks, Kara J. , Bach, Corrie, Paulsen, Andrew M, Camilleri, M , Navin, Patrick , Ryks, Michael, Johnson, Derek R., Camilleri, Michael

Mayo Clinic

Neurogastroenterology & Motility | February 13, 2026 | Volume: 38 | Issue: 2 | Pages: No page available

10.1111/nmo.70268 | PMID 41681033 Get It

ABSTRACT Background Gastric emptying (GE) scintigraphy with 4‐h imaging and a radiolabeled chicken egg‐based meal (320 kcal, 30% fat) is the standard test for gastroparesis at Mayo Clinic, with an intraindividual coefficient of variation (COV intra ) of 23.8% for GE half emptying time (T 1/2 ). Alternative meals for patients with dietary restrictions, including egg allergies or vegan diets, are lacking, limiting test accessibility. The study aimed to establish a vegan, lactose‐, nut‐, and gluten‐free meal with similar caloric and fat content to the egg meal and to assess its performance in GE studies. Methods In Vitro: 99m Tc binding to egg meal over 4 h was compared to a calorically and nutritionally similar vegan alternative, JUST Egg, using a validated in vitro model simulating gastric conditions of pH, pepsin, and stirring. In Vivo: 10 healthy participants underwent randomized crossover GE scintigraphy with standard and vegan meals, spaced ≥ 3 days apart to measure GE% at 2 h, 4 h, and GE T 1/2 . Group comparisons and variance analysis included Rank Sum tests and Bland–Altman plots. Key Results In Vitro: A strong correlation ( R = 0.975, p ‐value < 0.01) between 99m Tc binding in the egg and vegan egg models was observed. Minimal variance (< 10%) was recorded at all time points. In Vivo: GE at 4 h and GE T 1/2 showed non‐statistically significant mean differences, < 2% and < 10 min respectively, between both meals. The intra‐individual variability was 18.8%. Conclusions and Inferences The vegan meal demonstrated in vitro stability, in vivo performance comparable to the egg meal, and a COV intra of 18.8%, which was lower than the 23.8% reported in repeat egg meal GE studies. Trial Registration ClinicalTrials.gov number NCT06991036 ( https://clinicaltrials.gov/study/NCT06991036?term=NCT06991036&rank=1 )
Review of Cutaneous Manifestations in Myhre Syndrome With Histopathological Analyses and Genotype–Phenotype Correlation
Mittal, Setu , Johnson, Emma F. , Schimmenti, Lisa A. , Mohandesi, Nessa Aghazadeh, Aghazadeh, Nessa , Schimmenti, Lisa A , Aghazadeh Mohandesi, Nessa , Mittal, Setu

Mayo Clinic

American Journal of Medical Genetics Part C: Seminars in Medical Genetics | February 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmgc.70005 | PMID 41680107 Get It

ABSTRACT Myhre syndrome is a rare multisystem disorder characterized by distinctive facial features, hearing loss, and progressive fibrosis affecting the skin, joints, lungs, and cardiovascular system. It is caused by heterozygous pathogenic variants in the SMAD4 gene. In this review, we detail the cutaneous manifestations observed in two previously reported patients with genetically confirmed Myhre syndrome. While skin biopsies demonstrated pan‐dermal thickening of collagen bundles, the immunohistochemical staining patterns were distinct from those seen in other inflammatory sclerosing disorders. Additionally, we conducted a comprehensive literature review of the cutaneous features associated with Myhre syndrome, identifying 175 patients with confirmed SMAD4 pathogenic variants. The most reported cutaneous finding was thickened or stiff skin (76%), followed by keratosis pilaris (22%) and impaired wound healing or abnormal scarring (18%). Genotype–phenotype analysis suggested a diagnostic delay in patients with the codon 496 variant, who were more frequently diagnosed in adulthood. This variant may also be associated with a milder cutaneous phenotype, highlighting the clinical heterogeneity of Myhre syndrome. These findings underscore the importance of recognizing cutaneous features as potential early diagnostic clues in patients with suspected Myhre syndrome.
Residual Stone Volume Predicts Health Care Consumption and Stone Events: Analysis of Two-Year Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett, Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Lipkin, Michael, Cuellar, David, Cobb, Kaitlan, Barsky, Robert, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Levin, Michael, Chi, Thomas, Stern, Karen L , Mueller, Thomas J. , Wolf, Jeanette, Jones, Loren, Lipkin, Michael E. , Cuellar, David, Barsky, Robert I, White, Mark, Chi, Thomas

Mayo Clinic

Journal of Endourology | February 12, 2026 | Volume: 40 | Issue: 3 | Pages: 328-334

10.1177/08927790261420565 | PMID 41674087 Get It

Purpose: The ASPiration to Improve Renal Calculi Removal Effectiveness study showed steerable ureteroscopic renal evacuation (SURE) with CVAC that significantly reduced residual stone volume at 30 days vs standard ureteroscopy (URS). This report presents 2-year health care consumption and stone events (SE) and their link to residual stone volume and other variables ( n = 101 at primary end point; n = 93 at 2 years). Materials and Methods: Logistic regression identified predictors of health care consumption events (HCEs), that is, emergency department visits, hospitalization, surgical retreatment, and SE across the study population. Incidence was compared between the treatment groups with Kaplan–Meier survival analysis. Results: At 2 years, residual stone volume was significantly associated with both HCEs and SE. For every 100 mm 3 increase in residual stone volume, the HCE risk increased by 50% to 54%, and the SE risk increased by 70%. Stone-free rate, the number of residual fragments (RFs), and RF total stone burden (based on diameter) were not predictors. Significantly fewer HCEs occurred in the SURE group (3 vs 20 events, p = 0.0004). Survival analysis confirmed this (4.3% vs 20%, log-rank p = 0.02), with a 73% risk reduction (hazard ratio 0.27, 95% Cl 0.09–0.80, p = 0.02). Fewer SE occurred in the SURE group, although not statistically significant. These subjects also had longer event-free survival. Conclusion: High-quality volumetric analysis supports evaluation of stone removal therapies, as residual stone volume predicts HCEs and SE. SURE significantly reduces the downstream incidence and risk of HCEs compared with standard URS.
AI‐enhanced Centiloid quantification of amyloid PET images
Bourgeat, Pierrick , Fripp, Jurgen, Lebrat, Léo , Xia, Ying, Zisis, Georgios , Goyal, Manu S., Tosun, Duygu, Benzinger, Tammie LS., Breakspear, Michael J, Short, Cathy, Adam, Robert , Robertson, Joanne, Sperling, Reisa, O'Bryant, Sid E., Johnson, Sterling C., Jr, Clifford R. Jack, Schwarz, Christopher G., Barkhof, Frederik, Farrar, Gill , Bollack, Ariane, Collij, Lyduine E., Landau, Susan, Koeppe, Robert, Initiative, for the Alzheimer's Disease Neuroimaging, OASIS3, Team, the A4/LEARN Study, Team, The Health and Aging Brain Study (HABS‐HD) Study, WRAP, ADNI‐DOD, PISA, ADNeT, Morris, John C., Weiner, Michael W., Villemagne, Victor L., Masters, Colin L., Rowe, Christopher C., Doré, Vincent , Barkhof, Frederik , Bourgeat, Pierrick , Xia, Ying , Barkhof, Frederik , Xia, Ying , Doré, Vincent , Fripp, Jürgen , Xia, Ying, Feizpour, Azadeh , Cox, Timothy O. , Gillman, Ashley , Goyal, Manu S. , Benzinger, Tammie L.S. , LaMontagne, Pamela , Breakspear, Michael J , Lupton, Michelle K. , Short, Cathy, Sperling, Reisa Anne , O’Bryant, Sid E. , Johnson, Sterling C. , Jack, Clifford R. , Schwarz, Christopher G. , Bollack, Ariane , Collij, Lyduine , Landau, Susan , Koeppe, Robert A. , Initiative, for the Alzheimer’s Disease Neuroimaging, Morris, John C. , Weiner, Michael W. , Villemagne, Victor L. , Masters, Colin L. , Rowe, Christopher Cleon

Mayo Clinic

Alzheimer's & Dementia | February 11, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71162 | PMID 41670187 Get It

Abstract INTRODUCTION The Centiloid scale is the standard for amyloid (Aβ) PET quantification in research and clinical settings. However, variability between tracers and scanners remains a challenge. METHODS This study introduces DeepSUVR, a deep learning method to correct Centiloid quantification, by penalizing implausible longitudinal trajectories during training. The model was trained using data from 2,129 participants (7,149 Aβ positron emission tomography [PET] scans) in the Australian Imaging, Biomarkers and Lifestyle Study of ageing (AIBL)/Alzheimer's Disease Neuroimaging Initiative (ADNI) and validated using 15,807 Aβ PET scans from 10,543 participants across 10 external datasets. RESULTS DeepSUVR increased correlation between tracers, and reduced variability in the Aß‐negatives. It showed significantly stronger association with cognition, visual reads, neuropathology, and increased longitudinal consistency between studies. DeepSUVR also increased the effect size for detecting small treatment related slowing of amyloid accumulation in the A4 study. DISCUSSION DeepSUVR substantially advances Aβ PET quantification, outperforming all standard approaches, which is particularly important for clinical decision making and to detect subtle or early changes in Aβ. Highlights Novel artificial intelligence (AI)‐method that penalizes biologically implausible longitudinal trajectories, enabling the model to learn standardized uptake value ratios (SUVR) correction factors without requiring longitudinal data at inference time. Improves Centiloid consistency across tracers and studies, significantly enhancing cross‐sectional and longitudinal amyloid positron emission tomography (PET) quantification. DeepSUVR‐derived Centiloids show stronger associations with cognition, visual reads, and neuropathology. Longitudinal variability is reduced three‐ to five‐fold, enabling more reliable tracking of amyloid accumulation and better detection of treatment effects. Novel reference and target masks derived from DeepSUVR replicate most of the model's performance, offering a practical alternative for integration into existing pipelines.
A Decade of Impact: Outcomes and Opportunities From the College of American Pathologists Foundation Grants and Awards Program
Reese, Rebecca, Johnson, Curtiss, Rankenburg, Julia A., Wang, Tengfei, Ahmed, Aadil, Atiya, Samir , Reese, Rebecca

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2026 | Volume: 150 | Issue: 5 | Pages: 391-402

10.5858/arpa.2025-0461-oa | PMID 41461171 Get It

Context.— Pathology is essential to global health care, yet disparities remain in access to education and training. The College of American Pathologists (CAP) Foundation addresses these gaps through grants and awards that support trainees, early-career pathologists, and initiatives promoting equity worldwide. Since 2015, total funding has increased from $18,400 to $84,098, an astounding 357%. Objective.— To evaluate the CAP Foundation Grants and Awards Program during a 10-year period, assessing financial investment, award distribution, recipient characteristics, and impact. Design.— A mixed-methods retrospective study integrated (1) quantitative analysis of program data, (2) qualitative feedback from awardees, and (3) a quantitative award impact survey of past CAP Foundation awardees. Variables included demographics, award type, funding amounts, geographic distribution, and career stage. Surveys assessed professional development, mentorship, and long-term engagement with CAP. Results.— From 2015 to 2024, a total of 744 applicants submitted 760 applications, resulting in 355 awards across 14 categories. Applications increased more than 8-fold, peaking in 2023, with surges during the COVID-19 pandemic. Medical student applications grew from 1 in 2020 to 17 in 2024 (76% annual growth); 9 of 12 Medical Student Travel Award recipients (75%) entered pathology residency. Geographic disparities were noted, with smaller residency programs showing higher per capita application rates. Among 174 survey respondents, 129 (74%) reported networking benefits, 127 (73%) learning benefits, and 99 (57%) mentorship benefits, though only 49 (28%) sustained long-term mentoring relationships. Conclusions.— The CAP Foundation’s awards program has expanded access, supported career development, and fostered future pathologists. Strengthening long-term mentorship and bridging education-to-practice gaps may further enhance its impact.
Evaluating Vulnerable Elders Survey-13 and FIL Geriatric Assessment in Older Adults With Aggressive Lymphomas
Johnson, P. Connor, Newcomb, Richard A., Nipp, Ryan D., Horick, Nora , Stacey, Julia, Yang, Daniel, Coffey, Bridget , Markovitz, Netana, Kaslow-Zieve, Emilia , Venkatachalam, Shruthi , El-Jawahri, Areej, Odejide, Oreofe O. , Johnson, Patrick Connor , Newcomb, Richard Andrew , Nipp, Ryan David , Tsang, Mazie , Markovitz, Netana H. , Kim, Elane M. , El‐Jawahri, Areej

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: No page available

10.6004/jnccn.2025.7100 | PMID 41671426 Get It

Background: Aggressive non-Hodgkin lymphoma (aNHL) commonly occurs in older adults. However, geriatric assessments (GAs), which are associated with both survival and treatment-related toxicity, are infrequently performed due to logistical constraints. In this study, we examined how the brief, self-reported Vulnerable Elders Survey-13 (VES-13) screening tool and a comprehensive GA relate to clinical outcomes in this population. Methods: We conducted a longitudinal study of 105 adults aged ≥65 years who were initiating upfront chemoimmunotherapy for aNHL at 2 academic medical centers and their community affiliates between September 2020 and January 2023. Baseline frailty was evaluated using the Fondazione Italiana Linfomi (FIL) GA, which classifies patients as fit, unfit, or frail. The VES-13 was assessed both continuously and by categorizing patients as vulnerable (score ≥3). Using logistic regression controlling for covariates, we examined the association of VES-13 with grade ≥3 nonhematologic toxicity (toxicity), unplanned hospitalization within 6 months of treatment initiation, decline in quality of life (QoL) 1 year after therapy initiation, and death within 1 year of treatment initiation. In addition, we calculated the sensitivity and specificity of both the VES-13 and the FIL GA in identifying patients at risk for these outcomes. Results: The median patient age was 73 years (range, 64–99 years), with 42% aged ≥75 years. GA classified 40% of patients as fit, 10% as unfit, and 51% as frail, while 46% of patients had a VES-13 score ≥3, indicating vulnerability. VES-13 score was significantly associated with toxicity (odds ratio [OR], 1.18; P =.026), unplanned hospitalization (OR, 1.16; P =.043), QoL decline at 1 year (OR, 1.22; P =.027), and death within 1 year (OR, 1.49; P =.010). Using the VES-13 to define vulnerability (score ≥3), sensitivity and specificity were 59% and 61% for predicting toxicity, and 100% and 59% for predicting death within 1 year, respectively. FIL GA frailty had a sensitivity of 63% and specificity of 56% for predicting toxicity, and 100% sensitivity and 54% specificity for predicting death within 1 year. Conclusions: We found that VES-13 score was associated with survival, toxicity, health care utilization, and QoL decline, demonstrating similar sensitivity and specificity to the FIL GA. These findings underscore the potential utility of VES-13 as a screening instrument to identify older patients with aNHL at risk for adverse clinical outcomes.
Engineering the Future of Heart Failure Therapeutics: Integrating 3D Printing, Silicone Molding, and Translational Development for Implantable Cardiac Devices
Eagle, Carleigh , Desai, Aarti , Franklin, Michael J. , Pooley, Robert A. , Johnson, Elizabeth Oluwanifemi, Robinson, Shawn , Lopez, mark, Goswami, Rohan, Goswami, Rohan , Franklin, Michael, Pooley, Robert, Johnson, Elizabeth , Goswami, Rohan M , Desai, Aarti , Franklin, Michael, Johnson, Elizabeth

Mayo Clinic

Bioengineering | February 9, 2026 | Volume: 13 | Issue: 2 | Pages: 192

10.3390/bioengineering13020192 | PMID 41749732 Get It

Three-dimensional (3D) anatomic modeling derived from high-resolution medical imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), has been increasingly adopted in preclinical testing and device development. This white paper describes a cardiac-specific workflow that integrates 3D printing and silicone molding for support device development and procedural simulation. Patient-derived computed tomography angiography data were segmented using FDA-cleared medical modeling software to isolate the left ventricular anatomy and were further processed in computer-aided design (CAD) to ensure accurate physiological wall thickness and structural fidelity. Material jetting 3D printing was performed on a Stratasys J750 using material distributions designed to mimic the mechanical properties of myocardium, thereby approximating myocardial compliance. In parallel, stereolithography apparatus molds were designed from the left ventricle CAD model to cast transparent, pliable left ventricular models in Sorta-Clear™ 18 silicone. The 3D-printed models preserved intricate morphological detail and were suitable for mechanical manipulation and device deployment studies, whereas silicone models offered tunable mechanical properties, transparency for visualization, and durability for repeated use. Together, these complementary modalities provided rapid manufacturing capability and application-relevant physical representation. Case-specific parameters, strengths, and limitations of both models in enhancing patient care and device testing are highlighted, with relevance to heart failure applications. Current knowledge gaps, workflow and integration challenges, and future opportunities are identified, positioning this work as a reference framework for continued innovation in anatomic modeling. Within the collaborative framework of Mayo Clinic’s Anatomic Modeling Unit and Simulation Center, this integrated modeling workflow demonstrates the value of multidisciplinary collaboration between engineers and clinicians. Clinically, these patient-specific left ventricular models may enable pre-procedural device sizing and positioning and may support simulation of mechanical circulatory support (MCS) deployment while identifying possible anatomic constraints prior to intervention. This workflow has direct applicability in advanced heart failure patients undergoing MCS support, such as the Impella axillary MCS device or the durable LVAD, with potential to reduce procedural uncertainty while reducing complications and improving peri-procedural outcomes. Additionally, these models also serve as high-accuracy educational tools, enabling trainees and multidisciplinary care teams to visualize and possibly rehearse procedural steps while gaining hands-on experience in a risk-free environment.
Underreported Demographic Factors in Apraxia of Speech Treatment Studies: Recommendations for Inclusive Research
Bislick, Lauren , Utianski, Rene L., King, Charlotte , Nealon, Kate , Johnson, Rachel K. , Haley, Katarina L. , Utianski, Rene L. , Utianski, Rene L , Johnson, Rachel , Haley, Katarina L , Wambaugh, Julie L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | February 5, 2026 | Volume: 69 | Issue: 3 | Pages: 998-1006

10.1044/2025_jslhr-25-00532 | PMID 41642095 Get It

Purpose: While acquired apraxia of speech (AOS) has been the focus of intervention research for decades, little information is reported about the demographic representation of study participants. This article examines the extent to which published AOS treatment studies report participants' age, sex/gender, race/ethnicity, language background, and socioeconomic status; identifies critical gaps in the literature; and considers implications for representativeness. This information supports the important call to capture these patient factors systematically and thereby advance equity in research and clinical care. Method: This study is part of a larger systematic review examining treatment outcomes for acquired AOS. A comprehensive search of databases from 1951 to April 2024 was completed to determine the proportion of treatment articles that reported demographic information related to diversity. Studies were reviewed by trained raters using a standardized data extraction protocol with a consensus protocol. Results: While participant age and sex/gender were reported in nearly all studies (99% and 100%, respectively), only 24% of studies reported on race/ethnicity, 15% provided information on participants' language background, and none reported socioeconomic status. Among studies that included race/ethnicity, 89% of the participants were White, with minimal representation of other racial/ethnic groups. Conclusions: The underreporting of race/ethnicity, language background, and socioeconomic factors limits the generalizability and ecological validity of AOS treatment research. The field must prioritize inclusive participant recruitment and consistent demographic reporting. We propose a practical template for use in both research and clinical contexts to support more thorough data collection and to inform future work in diagnosis, assessment, and intervention for AOS. Supplemental Material: https://doi.org/10.23641/asha.31172353
AI-driven voice analysis for early fluid overload detection in heart failure: preliminary results from the DHZC cohort of the VAMP-HF study
Riehle, L, Fouad, M, Hott, M, Lee, C B, Vungarala, Soumya , Johnson, B, Olson, L, Hindricks, G, Riehle, Leonhard , Fouad, Mariam , Hott, Marcus, Heil, Emanuel , Olson, L. J., Hindricks, Gerhard , Hohendanner, Felix

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.4423 Get It

Abstract Background Effective fluid status monitoring in chronic heart failure (HF) patients is critical for preventing decompensation and hospitalization. Conventional methods, such as daily weight tracking, often fail to detect early, pre-symptomatic fluid retention. As fluid accumulation affects the vocal tract, subtle voice alterations can serve as a biomarker for congestion. In this work, we present preliminary results from the first 55 patients enrolled at the German Heart Center at Charité (DHZC) within the multicenter VAMP-HF study, assessing the performance of AI-driven voice analysis for non-invasive fluid status monitoring. Methods The study design incorporated a run-in period for the first 20 patients to refine the recording setup and ensure sufficient audio quality for subsequent data collection. An additional three patients were excluded due to clinical deterioration or in-hospital mortality. Participants provided daily voice recordings (sustained vowels, standardized text, and varying sentences) alongside clinical measurements such as NT-proBNP, daily weight, and left-ventricular ejection fraction. A speaker-independent XGBoost classifier was trained on acoustic features to classify patient states (admission, discharge, and intermediate states). Performance was evaluated using a nested leave-one-patient-out approach, ensuring strict training and validation data separation. Results The final analysis included 32 patients (mean age 76.12 ± 12.65 years). At admission, patients had a mean NT-proBNP of 9575.55 ± 8202.87 pg/mL and a mean weight loss of 4.2 ± 4.29 kg until discharge. The trained machine learning model achieved an F1-score of 0.75 (Fig. 1b), demonstrating its ability to distinguish between admission and discharge states, based solely on voice samples. An exemplary prediction for a test patient is shown in Fig. 1a. Notably, the model was also able to detect subtle vocal changes even in patients with &lt;2 kg weight loss. Conclusion Our findings suggest that AI-driven voice analysis is a feasible biomarker for detecting heart failure decompensation. While not directly compared with conventional early warning thresholds, these results support the hypothesis that voice-based biomarkers may serve as an early indicator of fluid congestion. Further validation in larger cohorts is needed to confirm these findings and enable integration into remote HF monitoring programs.